Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 276 participants.
Also called NCT03760965
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 276 participants
- Sponsor
- Registry
-
NCT03760965
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Terminated
Technical summary
Registry record NCT03760965. Randomized; double masking; primary purpose treatment. Start 2018-11-27 (actual); primary completion 2020-04-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- sotagliflozin (SAR439954)
- Intervention (Drug)
- placebo
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct03760965- Content hash
46950647dac71e11e273782a0a5127879f8685e10254090e4a8e7f1acfba8dfa